- Activ8Insights Newsletter
- Posts
- Weekly Wrap Up: Sunday 11/2/2025
Weekly Wrap Up: Sunday 11/2/2025
Activ8 News Team
November 02, 2025
This Week in Activist Short Selling
This week saw five new activist short reports with dramatically varied market reactions, underscoring the unpredictable nature of short campaigns in the current bull market. While initial intraday reactions ranged from modest declines to dramatic plunges exceeding 28%, end-of-week results told a different story.
- Ducommun Inc. (DCO) faced forensic accounting allegations from Glass House Research, initially recovering to close flat but ending the week down 1.42% as investors digested the detailed accounting concerns.
- F5, Inc. (FFIV) sustained the week's worst damage from Deep Specter Research's cybersecurity breach exposé, finishing down 12.86% as serious investor concerns mounted about long-term reputational damage.
- Anavex Life Sciences (AVXL) saw muted response to BMF Reports' clinical trial criticism, closing the week down just 1.60% as biotech investors await the imminent EMA decision.
- Eos Energy Enterprises (EOSE) defied Fuzzy Panda Research's fraud allegations, remarkably recovering from an 8.49% intraday drop to finish the week up 11.55%, demonstrating strong buying support despite serious safety concerns.
- Datavault AI (DVLT) plummeted 28.57% intraday following Wolfpack Research's damning exposé of the stock promotion, closing the week down 19.44% as the market repriced the company amid allegations of a CEO with SEC sanctions and a non-functional platform.
New Activist Reports
Ducommun Inc. DCO
NYSE | Glass House Research
| Metric | Price | % Change |
|---|---|---|
| Close (Day Before) | $93.07 | — |
| Low (Report Date) | $88.20 | -5.23% |
| Close (Report Date) | $93.08 | +0.01% |
| Close (End of Week) | $91.75 | -1.42% |
DCO initially dropped 5.23% intraday following the Glass House Research report but mounted an impressive same-day recovery, closing essentially flat at $93.08. However, as investors had more time to analyze the detailed forensic accounting allegations, the stock declined gradually through the week, ultimately finishing down 1.42% at $91.75. This delayed negative reaction suggests the market is taking the accounting red flags seriously despite the initial resilience.
Ducommun Incorporated is a NYSE-listed aerospace and defense supplier based in Carson, California, providing structural and electronic components for both military and commercial applications. With approximately $795 million in revenue for 2024 and led by CEO Stephen Oswald since 2017, the company has positioned itself as a growth story in the aerospace sector with a "Vision 2027" target of $1.3-1.5 billion in revenue.
- Glass House alleges DCO is a "forensic accounting red flag disguised as an aerospace growth story" with revenue expansion driven by aggressive revenue recognition rather than genuine demand
- Report claims ballooning working capital and steady acquisition stream designed to mask weak organic performance
- Former insiders cited saying management doubled down on production despite project delays and shipment push-outs from Boeing, RTX, and Airbus
- Research firm warns a "big bath" period is highly likely as years of aggressive pull-forwards collide with reality
- Price target of $25-35 per share represents 40-60% downside from current levels
F5, Inc. FFIV
NASDAQ | Deep Specter Research
| Metric | Price | % Change |
|---|---|---|
| Close (Day Before) | $290.41 | — |
| Low (Report Date) | $261.50 | -9.95% |
| Close (Report Date) | $267.58 | -7.86% |
| Close (End of Week) | $253.05 | -12.86% |
FFIV experienced the most significant and sustained damage of any report this week. The stock plummeted nearly 10% intraday to $261.50 before recovering slightly to close down 7.86% at $267.58. Unlike other targets that recovered, F5 continued declining through the week, ultimately finishing down 12.86% at $253.05. This persistent selling pressure reflects serious investor concerns about the long-term implications of the alleged nation-state breach and potential damage to F5's reputation as a trusted cybersecurity provider.
F5, Inc. is a NASDAQ-listed cybersecurity and application delivery company, best known for its BIG-IP product line that helps secure and manage network traffic for enterprises worldwide. As a critical infrastructure provider serving government agencies, financial institutions, and major corporations, F5's products are deployed on over 600,000 devices globally, making any security compromise potentially catastrophic.
- Deep Specter alleges F5 is "a compromised cybersecurity company misleading the market" about a nation-state breach affecting 600,000+ devices globally
- Report claims attackers had 12+ months of unrestricted access to steal source code, vulnerabilities, and customer configurations
- CISA emergency directive warns of "potentially catastrophic compromise" requiring immediate federal action
- Research firm accuses F5 of prioritizing optics over substance, using inadequate consulting firms instead of deep forensic investigation
- Report concludes the breach enables attackers to decrypt significant portions of global Internet traffic and is far from contained
Anavex Life Sciences Corp. AVXL
NASDAQ | BMF Reports
| Metric | Price | % Change |
|---|---|---|
| Close (Day Before) | $8.10 | — |
| Low (Report Date) | $7.88 | -2.72% |
| Close (Report Date) | $8.02 | -0.99% |
| Close (End of Week) | $7.97 | -1.60% |
AVXL showed the most muted reaction of the week, declining just 2.72% intraday before stabilizing to close down under 1% at $8.02. The stock remained relatively flat through week's end, finishing down only 1.60% at $7.97. This minimal impact likely reflects a biotech investor base that's accustomed to volatility and short seller reports, combined with market participants focusing on the upcoming EMA decision in November-December as the true catalyst that will validate or refute BMF's thesis about failed trial endpoints.
Anavex Life Sciences Corporation is a NASDAQ-listed clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease and Rett syndrome. Operating from a virtual mailbox and having spent over a decade in development, the company has been pursuing regulatory approval in Europe for its lead drug candidate, with an EMA decision expected in late 2025.
- BMF Reports alleges AVXL is a "promotion-and-dilution machine disguised as biotech innovation" that has manipulated trial endpoints and conducted statistical gymnastics
- Report claims failed functional endpoints with ADCS-ADL showing p=0.36 (not statistically significant)
- Research firm points to "statistically implausible" Rett syndrome data with Cohen's d ≈ 1.9 and court-established scienter regarding endpoint deception
- BMF expects imminent EMA rejection in November-December 2025 as key catalyst
- Price target of $0.60-$0.85 per share represents 60-80% downside, valuing company at approximately $50-70M in net cash
Eos Energy Enterprises Inc. EOSE
NASDAQ | Fuzzy Panda Research
| Metric | Price | % Change |
|---|---|---|
| Close (Day Before) | $14.37 | — |
| Low (Report Date) | $13.15 | -8.49% |
| Close (Report Date) | $14.32 | -0.35% |
| Close (End of Week) | $16.03 | +11.55% |
In a remarkable display of market resilience, EOSE defied Fuzzy Panda's serious fraud allegations to deliver the week's most surprising performance. After initially plunging 8.49% to $13.15, the stock recovered to close the report day down just 0.35% at $14.32. Rather than succumbing to the damning allegations of deadly gas leaks and falsified financials, EOSE surged through the week to finish up 11.55% at $16.03. This dramatic reversal suggests either strong conviction buying from investors skeptical of the allegations, potential short covering, or market participants betting on government support given the DOE's $303M loan commitment.
Eos Energy Enterprises Inc. is a NASDAQ-listed battery storage company developing zinc-based energy storage systems as an alternative to lithium-ion batteries. The company has received significant government support including a $303 million Department of Energy loan program and has positioned itself as a key player in the renewable energy storage market. Based in the United States, EOSE has been working to commercialize its battery technology for large-scale energy storage applications.
- Fuzzy Panda alleges EOSE is "a fraudulent battery company" hiding deadly gas leaks and presenting false financials to government creditors
- Report claims batteries leak potentially deadly hydrogen bromide gas exceeding OSHA safety limits by 10x, with former safety executive warning: "You're literally riding the razor's edge on whether or not you'll kill somebody"
- Research firm alleges three different sets of financial models presented to mislead DOE, Cerberus, and investors, with catastrophic unit economics (material costs of $284/kWh exceed selling prices of $250/kWh)
- Report claims approximately 80% of backlog consists of defunct or fictitious projects, with major customers abandoning the product
- Fuzzy Panda estimates 88% downside from comparable valuations, warning of DOE loan default risk with $90.9M debt potentially becoming immediately due
Datavault AI DVLT
NASDAQ | Wolfpack Research
| Metric | Price | % Change |
|---|---|---|
| Close (Day Before) | $2.52 | — |
| Low (Report Date) | $1.80 | -28.57% |
| Close (Report Date) | $2.03 | -19.44% |
| Close (End of Week) | $2.03 | -19.44% |
DVLT suffered the most dramatic intraday collapse of the week, plummeting 28.57% to $1.80 following Wolfpack Research's devastating exposé of what they called a "total joke" stock promotion. The stock recovered somewhat to close at $2.03 (down 19.44%) and held that level through week's end. This 19% sustained loss represents a significant repricing as the market absorbed Wolfpack's allegations about the SEC-sanctioned CEO, the company operating from a beauty salon, a non-functional blockchain platform with virtually no trading activity, and questionable partnerships with cash-strapped penny stock companies.
Datavault AI is a NASDAQ-listed company that claims to operate a "blockchain-powered AI platform" for data monetization and NFT trading. Led by CEO Nathaniel Bradley and operating from a 2,800 square foot office (not the claimed 22,000 sq ft), the company has announced various partnerships and initiatives including quantum computing centers and AI defense contracts. The company's leadership operates from locations including a beauty salon in Matawan, New Jersey, and New York City co-working spaces.
- Wolfpack alleges DVLT is a stock promotion led by CEO Nathaniel Bradley, who was fined $40,000 by the SEC in 2021 for falsely claiming his previous company had COVID-19 tests and PPE "available" when the company was actually insolvent
- Report claims the "Data Vault" platform is a wasteland with meaningless NFTs like "Bentley Pup" and "Parmesan Cheese," finding only ONE transaction in over 100+ NFTs reviewed - a 1 penny trade from May 2023
- Research reveals the "22,000 square foot quantum computing center" is actually a 2,800 sq ft office where only one employee was observed working
- Report exposes partnerships with questionable companies: Burke Products (a small Ohio business selling nuts and bolts, not AI defense tech) and Nature's Miracle Holdings (which has only $9,511 in cash despite promising a $2M license fee)
- Wolfpack concludes Bradley operates the ~$700M market cap company from a beauty salon in New Jersey and that DVLT is designed to enrich insiders at retail investors' expense
Activ8 Newswire
Despite a challenging environment with the S&P 500 hitting new highs, activist short sellers like Carson Block of Muddy Waters are thriving by using risk management strategies such as covering positions quickly after publishing reports, hedging with long positions, and trading around their shorts to navigate the extended bull market.
Read Article →The UK's Financial Conduct Authority confirmed it will stop publishing the identities of short sellers and instead only disclose anonymised aggregate net short positions, aligning Britain more closely with U.S. disclosure practices in an effort to cut red tape and make the country's markets more competitive for hedge funds.
Read Article →Citron Research founder Andrew Left is suing Anson Advisors and its leaders, alleging they falsely told the Securities and Exchange Commission that he orchestrated a scheme to funnel short-selling proceeds through a third party in an effort to deflect blame and protect themselves in the federal government's fraud case against him.
Read Article →Activ8Insights.com is your go-to source for everything in the world of activist short selling. We track every activist short report as it drops, publish in-depth analysis on targeted companies, and scour the web for related news and filings, so you don’t have to. Whether you're an investor, analyst, or just short-curious, we bring the red flags to your inbox in real time.
Visit our Website
Disclaimer
The information provided on Activ8Insights.com—including all articles, reports, commentary, and associated content—is intended solely for informational and educational purposes. It does not constitute investment advice, an offer, or a recommendation to buy or sell any securities. Activ8Insights does not express any opinion on the valuation or future performance of any security mentioned. All views and opinions presented aim to promote transparency and critical dialogue around activist investing—particularly short activism—but should not be interpreted as personalized financial advice. Investors are solely responsible for their own due diligence and investment decisions, based on publicly available information and their individual financial circumstances. We strongly encourage consulting a licensed financial advisor before making any investment decisions. No content published by Activ8Insights constitutes a solicitation or offer to buy or sell securities or financial instruments. Authors, contributors, or affiliates of Activ8Insights may hold long or short positions in the securities mentioned. These positions may change at any time without notice, and there is no obligation to disclose such changes after publication. Any forecasts, estimates, or forward-looking statements are speculative by nature and based on assumptions that may prove inaccurate. They are subject to risks, uncertainties, and change without notice. Activ8Insights makes no commitment to update forward-looking content. Activ8Insights disclaims all liability for any direct or consequential loss arising from the use of content on this site or associated platforms. By accessing this website or our affiliated media, you acknowledge and agree to this disclaimer and our terms of use. Unauthorized reproduction or distribution of this content is strictly prohibited and may result in legal action.